Press
Welcome to the press room of Dr. Werner Lanthaler – explore articles, interviews and highlights of Dr. Lanthaler’s contribution to pioneering innovation in Life Sciences & Sustainability.

What Does the Future Hold for European Biotech? Insights from Evotec’s CEO
"As the CEO of Evotec, one of Europe’s largest biotech companies, Werner Lanthaler is in a unique position to look into the future of the biotech industry. At Labiotech Refresh in Vienna, Lanthaler shared his views on where the industry is headed — and how to stay ahead of the game."

Interview with Europe’s Leader in Biotech Partnerships
"I talked with Werner Lanthaler, CEO of Evotec, during Bio Europe 2017 to ask him what the key is to his company’s great success in supporting biotech innovation and establishing strategic partnerships. "

Evotec AG | CEO Dr. Werner Lanthaler: “We see further growth in outsourcing services”
In today’s interview we were able to ask our “five questions” to Dr. Werner Lanthaler, CEO of Evotec AG

Werner Lanthaler: Shaping the Future of Life Sciences and Sustainability Through Visionary Leadership
I am delighted to be part of a strong team and to have the opportunity to work together to sustainably improve the lives of people affected by allergic diseases. The impact on patients with allergies is enormous. It’s great to see how HAL Allergy is improving patients’ quality of life with its products.”

Beyond Capital: Werner Lanthaler’s Mentorship Philosophy for Emerging Biotech Entrepreneurs
As stated on the Wlanholding website, the company acts as an “entrepreneurial partner, offering hands-on experience and a down-to-earth approach” committed to supporting “passionate founders and management teams to reach the next critical stage of growth, transforming smart and innovative businesses into scalable organizations.”

Dr. Werner Lanthaler Appointed Chairman of aTENSION.life Following USD 3M Investment Led by Wlanholding
"Every hypertension patient deserves an early and precise diagnosis leading to a targeted treatment. This funding brings us one step closer in making clinical mass spectrometry diagnostics available to everyone."